Targeted COVID-19 Vaccination (TAV-COVID) Considering Limited Vaccination Capacities—An Agent-Based Modeling Evaluation

Author:

Jahn BeateORCID,Sroczynski GabyORCID,Bicher MartinORCID,Rippinger ClaireORCID,Mühlberger NikolaiORCID,Santamaria Júlia,Urach Christoph,Schomaker MichaelORCID,Stojkov IgorORCID,Schmid DanielaORCID,Weiss GünterORCID,Wiedermann UrsulaORCID,Redlberger-Fritz Monika,Druml Christiane,Kretzschmar MirjamORCID,Paulke-Korinek Maria,Ostermann HerwigORCID,Czasch CarolineORCID,Endel GottfriedORCID,Bock WolfgangORCID,Popper NikolasORCID,Siebert UweORCID

Abstract

(1) Background: The Austrian supply of COVID-19 vaccine is limited for now. We aim to provide evidence-based guidance to the authorities in order to minimize COVID-19-related hospitalizations and deaths in Austria. (2) Methods: We used a dynamic agent-based population model to compare different vaccination strategies targeted to the elderly (65 ≥ years), middle aged (45–64 years), younger (15–44 years), vulnerable (risk of severe disease due to comorbidities), and healthcare workers (HCW). First, outcomes were optimized for an initially available vaccine batch for 200,000 individuals. Second, stepwise optimization was performed deriving a prioritization sequence for 2.45 million individuals, maximizing the reduction in total hospitalizations and deaths compared to no vaccination. We considered sterilizing and non-sterilizing immunity, assuming a 70% effectiveness. (3) Results: Maximum reduction of hospitalizations and deaths was achieved by starting vaccination with the elderly and vulnerable followed by middle-aged, HCW, and younger individuals. Optimizations for vaccinating 2.45 million individuals yielded the same prioritization and avoided approximately one third of deaths and hospitalizations. Starting vaccination with HCW leads to slightly smaller reductions but maximizes occupational safety. (4) Conclusion: To minimize COVID-19-related hospitalizations and deaths, our study shows that elderly and vulnerable persons should be prioritized for vaccination until further vaccines are available.

Funder

Gordon and Betty Moore Foundation

Austrian Federal Ministry for Digital and Economic Affairs BMDW and handled by the Austrian Research Promotion Agency

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference47 articles.

1. Report 9: Impact of Non-Pharmaceutical Interventions (NPIs) to Reduce COVID19 Mortality and Healthcare Demandhttps://standpunkt.jetzt/wp-content/uploads/2020/07/COVID19-Report-9-Imperial-College.pdf

2. Quarantine alone or in combination with other public health measures to control COVID-19: A rapid review;Nussbaumer-Streit;Cochrane Database Syst. Rev.,2020

3. Universal screening for SARS-CoV-2 infection: a rapid review

4. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis

5. Draft Landscape of COVID-19 Candidate Vaccines 2021https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

Cited by 32 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3